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Abstract
Background: Studies report variation in the incidence and outcomes of encapsulating peritoneal sclerosis (EPS). This study
reports the incidence and outcome of EPS cases in a national cohort of peritoneal dialysis (PD) patients.
Methods: The incident cohort of adult patients who started PD between 1 January 2000 and 31 December 2007 in Scotland
(n = 1238) was identiﬁed from the Scottish Renal Registry. All renal units in Scotland identiﬁed potential EPS cases diagnosed
from 1 January 2000 to 31 December 2014, by which point all patients had a minimum of 7 years follow-up from start of PD.
Results: By 31 December 2014, 35 EPS cases were diagnosed in the 1238 patient cohort: an overall incidence of 2.8%. The
incidence for subgroups with longer PD duration rises exponentially: 1.1% by 1 year, 3.4% by 3 years, 8.8% at 4 years, 9.4%
at 5 years and 22.2% by 7 years. Outcomes are poor with mortality of 57.1% by 1 year after diagnosis. Survival analysis
demonstrates an initial above-average survival in patients who later develop EPS, which plummets to well below average
after EPS diagnosis.
Conclusions: The incidence of EPS is reassuringly low provided PD exposure is not prolonged and this supports ongoing use
of PD. However, continuing PD beyond 3 years results in an exponential rise in the risk of developing EPS and deciding
whether this risk is acceptable should be made on an individual patient basis.
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Introduction
Encapsulating peritoneal sclerosis (EPS) has been amajor focus of
the peritoneal dialysis (PD) literature in the past decade. Until the
pathophysiology is fully understood, causative factors are identi-
ﬁed, and reliable preventative or therapeutic strategies are avail-
able, it should remain a priority for research. We cannot yet
predict who will succumb but we can advise patients that
increasing duration of PD exposure is a clear risk factor for EPS
[1–3]. Nephrologists advise and guide decisions about dialysis
therapies, so it is easy to see why the potential for developing
EPS may dissuade some clinicians from commencing PD at all.
The decision whether to limit PD treatment duration, given the
clear association of EPS with prolonged PD, is contentious, not
least because of problems with incidence reporting [1, 2, 4–6].
Similarly, haemodialysis as the alternative option is not risk-
free and we will never have a randomized trial to compare
these modalities [7].
In 2009we published our initial work, quantifying the incidence
of EPS in an incident PD cohort [2]. The main motivation for carry-
ing out this studywas that no other published studies had reported
Received: December 7, 2015. Accepted:May 9, 2016
© The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
For commercial re-use, please contact journals.permissions@oup.com
Clinical Kidney Journal, 2016, vol. 9, no. 4, 624–629
doi: 10.1093/ckj/sfw051
Advance Access Publication Date: 20 June 2016
Original Article
624
C
L
IN
IC
A
L
K
ID
N
E
Y
JO
U
R
N
A
L
a true incidence andwere therefore potentiallymisleading. The in-
tention of our work was to achieve this in the Scottish PD popula-
tion, quantifying the incidence and recording the outcome of EPS
cases using the ISPD diagnostic criteria [8]. There is a view that
these criteria should be reﬁned to improve consistency of diagnosis
between studies and avoid potential over-reporting [8, 9].
Given that EPS is associated with duration of PD and many of
our patients had short exposure to PD by 2009, it was necessary to
follow our original cohort for several years to establish an accur-
ate incidence. In this paper we present the results of further
follow-up of the same PD cohort.
Materials and methods
Using the Scottish Renal Registry, we identiﬁed all adult patients
who started PD between 1 January 2000 and 31 December 2007 in
Scotland (n= 1238) and asked the 10 renal units to identify potential
EPS cases diagnosed on or after 1 January 2000. We continued the
data collection until 31 December 2014, by which point all patients
had achieved a minimum of 7 years follow-up from start of PD.
Diagnosis
We examined medical records to make sure cases met the ISPD
criteria for EPS diagnosis including clinical features and either
radiological and/or histopathological conﬁrmation [8]. Exclusion
criteria included the presence of an alternative cause for EPS: tu-
berculosis, previous abdominal surgery (except PD catheter or
transplant placement), active inﬂammatory bowel disease or pre-
vious bowel perforation, intraperitoneal chemotherapy, other
cause of ascites including malignancy or liver cirrhosis. Ten po-
tential caseswere excluded because therewas an alternative pos-
sible cause for their ﬁndings (n = 7) or there was insufﬁcient
radiological or pathological evidence to deﬁnitely diagnose EPS
(n = 3). Clinical details relating to underlying primary renal dis-
ease, exposure to high-strength dextrose and/or Extraneal/Ico-
dextrin dialysate, peritonitis episodes, radiological and/or
laparotomy/oscopy ﬁndings and any treatment given were col-
lected for all cases. Peritoneal equilibration tests (PET) are not
regularly performed in stable PD patients and there were not en-
ough PET results for meaningful analysis of any change in trans-
porter status around the time of EPS diagnosis.
Statistical analysis
Statistical analyseswere performed using SPSS® (version 19). The
incidence of EPS was calculated using the number of EPS cases
divided by number of patients on PD according to duration of
PD exposure. The Kaplan–Meier analysis was used to calculate
cumulative risk of EPS using the time from ﬁrst PD to EPS diagno-
sis, without censoring for transplantation (intention-to-treat
analysis). The Kaplan–Meier method was also used to compare
patient survival from start of PD to death or study end.
Ethics
This study represents audit of usual clinical care, and was there-
fore exempt from requiring ethics submission.
Results
Clinical presentation and diagnosis
The major clinical characteristics of the EPS cases are shown in
Table 1. Clinical presentation varied; overall 14/35 presented
with acute bowel obstruction and had classical EPS ﬁndings at
laparotomy. A further 15/35 had exploratory laparotomyor lapar-
oscopies that revealed typicalmatted, adherent bowel classical of
EPS. The remaining six cases were diagnosed on the basis of
symptoms with computed tomography (CT) (n = 4) or ultrasound
scan imaging (n = 2) conﬁrming the diagnosis.
Incidence and change in incidence over time
Between 1 January 2000 and 31 December 2007, 1238 patients
were ﬁrst exposed to PD. Table 2 shows the EPS incidence accord-
ing to duration of PD exposure and the changes in the incidence.
This gives an incidence of 8.7 per 1000 PD treatment years by 31
December 2007 and a rate of 13.6 per 1000 PD treatment years by
31 December 2014. There is a substantial increase in the propor-
tion developing EPS after 5 years of PD (1 in 7.8 patients at risk).
At the study end 753 patients had died (60.1%), 28 (2.3%) pa-
tients had been lost to follow-up by moving out of Scotland, 356
(28.8%) have a functioning renal transplant, 83 (6.7%) are on
haemodialysis, 7 (0.6%) on home haemodialysis and 14 (1.1%)
are on PD.
As-treated versus intention-to-treat analysis
If we plot the time from start of PD as total exposure, i.e. actual
days spent on PD therapy, the EPS risk rises exponentially
(Figure 1A). In practice, as shown in Table 2, 15.4% of patients
on PD for 7–8 years, and none over 8 years so far have developed
EPS. The survival analysis shows us the accumulated risk (as-trea-
ted) of EPS; if a patient manages to continue on PD for 8 years the
risk of having developed EPS by that point is 40%. Figure 1B shows
an intention-to-treat EPS-free survival curve from start of PD
to EPS diagnosis only censoring at death or end of follow-up
(31 December 2014). By 5 years, <3% and by 10 years just under
5% of patients will have developed EPS, reﬂecting the reality
that few continue PD beyond 3 years because of death, technique
failure or renal transplantation.
Mortality
By the 31 December 2014, 29/35 (82.9%) of the patients who had
developed EPS had died with a 1-year mortality of 57.1%, with
no signiﬁcant different between PD exposure categories (Table 1),
although those with >6 years of PD exposure show a trend to-
wards highermortality (CHI square P = 0.08). Themedian survival
was 288 days [range 4–2493, interquartile range (IQR) 50–1151
days] from EPS diagnosis. Of note, 11/14 (78.6%) of those present-
ing with acute bowel obstruction were dead by 2 years post-
diagnosis compared with 13/21 (61.9%) of those with an alterna-
tive presentation.
The survival from start of PD to death is a median of 2382 days
for EPS cases (IQR 1599–3513 days) and 2482 days (IQR 880–3413
days) (P = not signiﬁcant) for thosewho did not develop EPS. How-
ever, those who developed EPS had better survival in the ﬁrst
3 years and thereafter, a steep fall in survival (Figure 2).
Discussion
We have accurately documented the incidence of EPS in a con-
temporary incident PD cohort in Scotland. The increase in inci-
dence between the initial data analysis in 2008 and the last
analysis in 2014 highlights the importance of length of follow-
up, particularly when the complication being studied is related
to duration of PD exposure [1, 2, 10, 11].
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Overall incidence
By virtue of the longer follow-upwebelieve the 2015 data analysis
provides the most accurate incidence; 2.8% overall. We can ﬁnd
no convincing evidence to suggest that the incidence is rising lo-
cally; it only appears to climb over the follow-up period because
the cohort’s PD exposure has increased. Indeed, fewer patients
have been diagnosed in our most recent than earlier data collec-
tions. It is unlikely that more patients will develop EPS from our
cohort given that so few patients are continuing PD beyond the
last data collection.
Our incidence is identical (2.8%) to the incidence reported in a
contemporary Italian study [3], similar to another UK series
(3.3%) [12] but higher than anAustralian study (0.7%) [1] and Japa-
nese and Korean studies (0.8–2.5%) [13–16]. Kawanishi published
a 2-year follow-up of a PD cohort in 2001, suggesting an incidence
of 0.8% [13], and further analysis in 2004 reporting an incidence of
2.5%, likely reﬂecting longer follow-up inherent to the study de-
sign rather than a true incidence increase [14]. Several publica-
tions from North America conﬁrm low overall EPS rates but
comparable, if not higher, rates for patients on PD for 5 years or
longer with one quoting an overall incidence of 1.2% but 15%
after 6 years on PD [5, 17–19]. Overall incidence is only one part
of the picture. Units with successful PD take-on rates and trans-
plantation programmes will have a high turnover and a dispro-
portionate number of patients on short-term PD, who will have
lower risk of EPS.
Incidence according to PD exposure
Our data conﬁrm the exponential rise in incidence with increas-
ing PD exposure; approximately 1:13with 4–5 years exposure, and
1:7.8 with 5–6 years exposure. A recent Italian study found rates
of 3%, 6%, 18% and 75% at 2–4 years, 6–8 years, 8–10 years and
12–14 years respectively [16]. Rigby et al.’s study showed rates of
1.9%, 6.4%, 10.8% and 19.4% at 2, 4, 5 and 8 years respectively [3]
which is similar to our own data. The rates are higher than in
Japan: 3 years 0%, 5 years 0.7% and 8 years 2.1%, but in that
4-year study the denominator population was all prevalent pa-
tients on PD so it is not a true incidence, and may underestimate
the rate [14]. Similarly, the retrospective nature of Johnson et al.’s
case–control study increases the likelihood ofmissing cases (they
found the incidence at 3 years was 0.3%, 5 years 0.8% and 8 years
3.9%) [11].
There are several potential reasons for differences in inci-
dence between centres and countries. One possible difference
is the use of ‘biocompatible’ or low GDP dialysis ﬂuids, which
Table 1. Clinical characteristics of EPS cases
EPS cases characteristics Number of cases
Age (median, IQR) 53 (43–65)
Male, n (%) 21 (60)
Primary renal diagnosis
APKD 8
DM 5
Unknown 10
FSGS 3
IgA 3
VUR 2
Congenital/familial 2
Light chain deposition 1
Other 1
Duration PD 1464 (1003–1934) days,
(median, IQR) 4.0 (2.7–5.3) years
Peritonitis
Never had peritonitis 3
Median number of peritonitis episodes
(IQR)
2 (1–3.5)
Number having fungal peritonitis 3
Number having staph aureus peritonitis 11
PD ﬂuid prescription
Icodextrin/Extraneal ever 33
High-strength dextrose (3.86% or
equivalent) ever
12
Solely biocompatible ﬂuid used 0
Betablocker or ACE/ARBa exposure, n (%)
Betablocker use while on PD 14 (40)
ACE or ARB use while on PD 9 (26)
On PD at diagnosis? n (%)
Yes 14 (40)
Nob 21 (60)
Functioning transplant at diagnosis 4 (11)
Diagnosis conﬁrmed by, n (%)
CT scan appearance 4 (11)
US scan appearance 2 (6)
Laparotomy or laparoscopy 29 (83)
Main presenting symptoms, n (%)c
Abdominal pain 21 (60)
Vomiting 20 (57)
Acute or subacute bowel obstruction 14 (40)
Ascites 9 (26)
Bloody ascites 3 (9)
Weight Loss 23 (7)
Abdominal distension (but not
obstruction)
5 (1)
Unexplained elevated CRP 11 (3)
CT scan (n = 27) or US scan (n = 2) ﬁndingsc
Bowel obstruction 9
Dilated bowel (not overt obstruction) 6
Matted/tethered bowel loops 18
Thickened mesentery/peritoneum 17
Thickened bowel wall 22
Loculated ascites 19
Peritoneal calciﬁcation 9
Management (n and % 1 year mortality)
No speciﬁc treatment 11 (72)
Tamoxifen 5 (20)
Tamoxifen and steroid 6 (50)
Taxoxifen/azathioprine 1 (0)
Sirolimus 2 (100)
Prednisolone only 4 (0)
Elective enterolysis/peritoneal stripping 2 (50)
Table continues
Table 1. Continued
EPS cases characteristics Number of cases
Attempted enterolysis during emergency
laparotomy
At least 6d (83)
APKD, adult polycystic kidney disease; DM, diabetes mellitus; FSGS, focal
segmental glomerulosclerosis; VUR, vesicoureteral reﬂux; ACE/ARB,
angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; US,
ultrasound; CRP, C-reactive protein.
aACE inhibitor or ARB drug treatment at some point while on PD.
bIncludes ﬁve diagnosedwithin 2weeks of stopping PDwhen symptomshad been
apparent (though not formally diagnosed) prior to transfer to haemodialysis
(three patients) or transplant (two patients).
cNote most patients had more than one.
dOperation notes not available or unclear if attempted adhesiolysis inmost cases.
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may be associated with a lower EPS risk [20]. They were not used
routinely in Scotland during this study period, which followed
the UK Renal Association PD Guidelines’ recommendation [21].
There has been a gradual move towards patients using ‘biocom-
patible’ ﬂuid in recent years and it will be interesting to record
whether the EPS incidence changes in future.
Diagnosis and timing of diagnosis
We used diagnostic criteria set out in the ISPD Guidance 2000 [8,
22]. A proportion of patients were highlighted to us for further
consideration who had not been given an EPS diagnosis locally,
but whom the nephrology team felt met criteria. It is relevant
that most of our EPS cases were diagnosed prior to CT imaging
diagnostic criteria being deﬁned, and the scans were reported
by ‘non-specialist’ radiologists in many cases [23–25]. Had we re-
lied upon units to simply report conﬁrmed EPS cases therewould
have been fewer cases.
We agree with the current belief that the diagnostic criteria
need to be standardized to allow proper comparative studies
to proceed [9]. One suggestion is to only include patients
with overt bowel obstruction, but it may be difﬁcult to deﬁne
obstruction [22].
Of our cases, there were patients who had unimpressive im-
aging (e.g. ascites only), and no overt bowel obstruction but
who undoubtedly had advanced EPS with a matted mass of
bowel at laparotomy. Only two casesmay be excluded if diagnos-
tic criteria were modiﬁed as suggested above; both had classical
symptoms and imaging showing loculated asciteswith adherent,
thickened bowel but without obstruction and did not undergo
laparotomy/oscopy to conﬁrm EPS, yet both died within
12 months of diagnosis. The signiﬁcant mortality for those with-
out overt obstruction does not equate to a more indolent disease
course in our case series.
The clinical characteristics (Table 1) are similar to previous-
ly published case series. EPS was diagnosed after stopping PD
in 60% of our cases, which is similar to Japanese data (69%) and
higher than in an Australian study (21%) [11, 14]. No patients
routinely receive peritoneal lavage after discontinuing PD in
Scotland. Nine patients had been transplanted although only
four (11%) cases were diagnosed with EPS with a functioning
transplant, compared with 3% in an Japanese series, 8% in
an Italian series, none in an Australian series and 25–29%
in a Dutch study [3, 11, 14, 26, 27]. This wide variation may
relate to differences in case ascertainment or PD duration
pre-transplant.
Fig. 1. (A) Cumulative risk of EPS with increasing exposure to PD (as-treated)
(censored at death or the end of study on 31 December 2014). (B) Incidence of
EPS from start of PD regardless of whether patient continues on PD or not
(intention-to-treat) (censored at death or the end of study on 31 December 2014).
Table 2. PD exposure and number of EPS cases for the incident PD cohort at the three different data collection periods
PD
exposure
(years)
2008 analysis 2009 analysis 2015 analysis
1 year
mortality
rate
PD
cohort
(n)
EPS
cases
(%)
Incidence
(%)
PD
cohort
(n)
EPS
cases
(%)
Incidence
(%)
PD
cohort
(n)
EPS
cases
(%)
Incidence
(%)
95%
conﬁdence
intervals
≤1 480 0 0 470 1 0.2 419 1 0.2 0.04–1.3 0
>1–2 326 2 0.6 327 3 0.9 282 3 1.1 0.4–3.1 66%
>2–3 202 4 2.0 198 5 2.5 208 7 3.4 0.9–5.8 29%
>3–4 114 4 3.5 117 6 5.1 135 6 4.4 1.0–7.9 67%
>4–5 62 5 8.1 63 6 9.5 80 7 8.8 2.6–14.9 57%
>5–6 34 3 8.8 35 6 17.1 53 5 9.4 1.6–17.3 60%
>6–7 15 1 6.7 17 3 17.6 33 4 12.1 1.0–23.3 75%
>7–8 5 0 0 11 1 9.1 9 2 22.2 0–49.0 100%
>8 – – – – – – 19 0 – – 66%
Total 1238 19 1.5 1238 31 2.5 1238 35 2.8 2.0–3.9 57.1%
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Outcome
Patient survival with EPS is poor; themortality rate for our cohort
was 57.1% at 1 year after diagnosis and 67.7% by the study end.
This ﬁnding compares with 37.5% [14] in Japan, and 56% [23]
and 29.6% [12] in UK series. We have not found a relationship be-
tween mortality and duration of PD before EPS diagnosis despite
Japanese data showing those diagnosed with EPS after longer PD
exposure experienced exponentially higher mortality [14].
The ﬁnding that the median survival from start of PD to pa-
tient death is comparable for EPS cases and the PD population
in general is perhaps misleading. Patients who develop EPS
may have been among the ﬁtter PD patients, having survived
long enough on PD to get EPS. Figure 2 illustrates this whereby
the survival curves initially diverge and the EPS patients have a
better survival rate until around 4 years when the survival curves
converge, and then cross as the EPS cases’ survival dramatically
falls off. This corresponds to the timing of EPS diagnosis and high
mortality thereafter.
Wehave limited data regarding the dose and duration ofmed-
ical therapies or details of exact surgical intervention at laparot-
omy for the majority of cases. The 1-year mortality (83%) for the
six cases who had documented attempts at peritoneal stripping
and/or division of adhesions during exploratory laparotomy de-
monstrates the potential poor outcome of non-specialist, un-
planned surgical intervention for EPS. Only two cases had
elective specialist enterolysis as this was not an option in the
UK until recent years.
Implications of our results for clinical practice
When considering the risk of EPS for speciﬁc patients, there are
two main scenarios: patients already established on treatment
and patients considering starting PD. For patients already on
PD, our incidence data quantify the risk of developing EPS for a
given duration of PD (Table 2). By 2 years of PD the EPS risk is neg-
ligible, but after 5 years it is above 1 in 10. The risk of continuing
PD for a patient awaiting renal transplantation after years of PD
may be considered to be too great, whilst the same risk for a pa-
tient with no option for transplantation, no vascular access or no
haemodialysis centre nearby may be acceptable.
The second scenario is more difﬁcult, as when a patient com-
mences PD it is not known how long theywill continue PD or how
long they will survive. Intention-to-treat analysis allows quanti-
ﬁcation of the predicted risk of developing EPS. In general this ana-
lysis should be reassuring, as the vast majority of patients stop
PD for other reasons long before EPS is a signiﬁcant risk.
Whether PD duration should be limited is controversial. We
would argue that such decisions can only be made between an
individual patient and his or her clinician in the context of local
incidence and PD practice including assessment of peritoneal
function. We hope that our data could help inform such
decisions.
Limitations
If cases have been missed, the incidence we report is an under-
estimate. It was not the remit of our study to identify any predic-
tors of EPS development, but we have contributed our data to a
multinational study along with other large series in the hope
that it may help address this question.
Conclusions
Our data showaminimal risk of EPS before 2 years of PD, but a sig-
niﬁcant risk (1 in 10) beyond 5 years of PD treatment in Scotland.
Our data should reassure that the cumulative risk of developing
EPS after starting PD and the risk of EPS after short-term PD are
both low. This data may be used to inform long-term PD patients
and help them decide whether continuing on PD is a risk worth
taking.
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